Natera Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
21analysts covering
FY Revenue (est.)
$2.9Bnext fiscal year
FY EPS (est.)
-$1.41next fiscal year
Monitoring Framework
Key Performance Indicators
Total Processed Test Volume Quarterly1M
Clinical Oncology Test Volume Quarterly258.9K
Gross Margin Quarterly64.7%Target: 64 - 66%
Watch Items
- Signatera Commercial Launch in JapanTrigger: PMDA approval secured; commercial launch targeted by end of 2026Action: Monitor SRL national lab network integration and initial volume ramp
- Path to Profitability and Cash FlowTrigger: GAAP net loss of $85.1 million in Q1 2026Action: Track operating leverage, SG&A cost controls, and progress toward sustained positive net cash inflow
Research as of 2 Sep 2026